Vopratelimab is under clinical development by Concentra Biosciences and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase II drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vopratelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vopratelimab (JTX-2011) is under development for the treatment of solid tumors including head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), melanoma, urothelial cancer and gastric cancer. It is administered through intravenous route. The drug candidate acts by targeting the antigen CD278 (ICOS-inducible T-cell costimulator). It is developed based on translational science platform.
Concentra Biosciences overview
Concentra Biosciences is a bioscience company that develops novel immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of Vopratelimab’s drug-specific PTSR and LoA scores, buy the report here.